Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ATTO-1310

Other · developed by Attovia Therapeutics

Phase 2 Most advanced trial
ATTO Developer
1 Registered trials

What is ATTO-1310?

ATTO-1310 is an investigational drug studied in Chronic Pruritus of Unknown Origin.

At a glance

Drug type
Other
Therapy area
Dermatology
Developer
Attovia Therapeutics Inc (ATTO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07833306 Phase 2 Chronic Pruritus of Unknown Origin Not yet recruiting ATTO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Pruritus of Unknown Origin

More from Attovia Therapeutics

ATTO-1091 Phase 1 ATTO-3712 Phase 1

Follow ATTO, the company behind ATTO-1310

See ATTO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ATTO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.